substance p has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Keilani, MS; Alqudah, MA; Bdeir, R; Elstaty, RI | 1 |
| Ding, D; Hu, JL; Liu, XP; Ren, H; Wang, JG; Yang, WL; Yu, J; Zhang, L | 1 |
2 other study(ies) available for substance p and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.
Topics: Breast Neoplasms; Female; Hormones; Humans; Ki-67 Antigen; Pyruvate Kinase; Receptors, Neurokinin-1; Substance P; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2023 |
Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptors, Neurokinin-1; RNA Interference; RNA, Small Interfering; Signal Transduction; Substance P; Triple Negative Breast Neoplasms | 2015 |